Making Futures Possible

Since 1982

Research Gets Results

Because of research, the cancer death rate has decreased more dramatically for children than any other age group.

0 K
Children a year Diagnosed
0 K
Survivors of Childhood Cancer
Years of PCRF
Scientific Grants Awarded
Leading Institutions Funded
$ 0 M
invested in pediatric cancer research

Who We Are

Since 1982, the Pediatric Cancer Research Foundation has been chasing one ambitious goal:   to make it possible for all children facing childhood cancer to beat their disease and realize their full potential. We will achieve this by powering cures where none exists and giving rise to less toxic regimens that have fewer side effects.

While the challenge is huge, we are both optimistic and determined. We have raised and invested more than $54 million in pediatric cancer research that has contributed to groundbreaking advances in treatment — and we are just getting started.  In 2022, we turn 40 years young and we plan to use our insights, experience, and leadership to uncover promising new directions and drive momentum in pediatric cancer research.
We know that meaningful progress relies on investing in promising research that advances the learning cycle and yields new insights.  We know, too, that identifying breakthroughs means championing and nurturing the researchers who are moving science forward every day.  By working together — with the research community, our partners and kind-hearted supporters — we will give flight to the breakthroughs that will help transform pediatric cancer care.

Our Mission

Fund research to power cures that reduce the percentage of children who perish from cancer until that number reaches zero.

Our Vision

Make it possible for all children facing childhood cancer to beat their disease and achieve their full potential so they can realize happy, healthy, productive futures.

Our Purpose

The Pediatric Cancer Research Foundation improves the lives of children living with cancer by funding novel research to transform pediatric cancer care.  We focus on advancing treatments and protocols that will create cures where none exist and inspire less toxic regimens that have fewer side effects.  We believe that vibrant partnerships with the research community are essential for accelerating meaningful scientific progress — partnerships that endure and flourish as days turn into years and stomach-churning disappointments alternate with exhilarating wins. That is why we cultivate today’s research rock stars and tomorrow’s innovators with the same steadfast commitment, optimism, and belief.  Together, we will change the world of pediatric cancer care and make it possible for children facing childhood cancer to spread their wings and soar

Milestones of Progress

Innovations PCRF has contributed to through funding:

Curing Advanced B-Cell NHL

We were pivotal in curing advanced mature B-NHL in children and adolescents and in reducing their toxic exposure and length of therapy. The result: they can lead healthier lives in the future and spend less time in the hospital while receiving therapy.

CarT Cell Infusion

PCRF funded development of a new treatment approach pairing genetic engineering with immunotherapies and launched the first in-human protocol using T cells to target Leukemia.

This groundbreaking work:

  • Proved that when CAR-T cells are infused back into the same patient, they can mount full-blown immune attacks on tumor cells.
  • Contributed to state-of-the-art therapies weaponizing the body’s immune system that are at the forefront of immuno-oncology today

Immunotherapy advancements for Osteo

Our funding demonstrated the potential for immunotherapy to treat osteosarcoma, offering one of the only new treatments in almost 20 years. The breakthroughs = new treatments for A&YA patients who previously had no options.

JMML – Diagnostic Test

PCRF funded diagnostic tests that predict which patients are likely to respond positively to the intensive treatment to JMML

  • This risk stratification allows for treatment decisions to be optimized, giving patients a higher likelihood of success in a disease with 50% survival rate

AML - Advancement in Drug Therapy

Since 2008, PCRF funding has advanced treatments for children with acute myeloid leukemia (AML) and builds on the insight that a protein called CREB is overproduced in AML patients. Research has focused on developing newer and better drugs to block CREB – causing AML cells to die. One drug is now in Phase 1 Trials

Our History

The Pediatric Cancer Research Foundation is celebrating a milestone in 2022 – our 40th anniversary.  Over the past four decades, we have been at the vanguard of identifying and stewarding promising research.  With the help of parents, physicians, and volunteers the Foundation has raised and invested over $54 Million, all of which has supported pediatric cancer research.    

As we look to the future, we are a bit wistful that there is so much more to learn and do to beat the diseases that continue to rob children of their childhood.  More than anything, we are super charged to do more and with greater urgency. That starts with generating the funding pediatric cancer research needs to accelerate new treatment breakthroughs, to support the next generation of researchers, and to uncover promising new directions.  We like contributing to history – and with your help we will continue to rewrite it. 

The Behind the Scenes Team

Change a Life Today

Childhood is a short season. -Helen Hayes

Get involved today and start making the difference in a child’s life.